Journal of Integral Sciences (JIS)
(An International Open Access Journal)
Available at www.jisciences.com ISSN: 2581-5679

Nanotechnology-Based Drug Delivery Systems: Advances, Challenges, and Future Perspectives

Saamarth Venisetty[1], Sai Krishna Dodda[2], Raj Kumar Venisetty[3*]
[1]Chalmeda Ananda Rao Institute of Medical Sciences, Karimnagar - 505001, Telangana.
[2]Navodaya Medical College Hospital and Research Centre, Raichur, – 584 103, Karnataka.
[3]Pratishtha Institute of Pharmaceutical Sciences, Durajpally, Chivvemla, Suryapet - 508214, Telangana.

Received: 11 January 2022 Revised: 04 Feb 2022 Accepted: 16 March 2022

Abstract
Nanotechnology has emerged as a promising approach for improving drug delivery by overcoming several limitations of conventional pharmaceutical dosage forms. Nanocarriers, including liposomes, polymeric nanoparticles, lipid nanoparticles, micelles, and nanocrystals, can improve drug solubility, protect therapeutic agents from degradation, modify drug-release patterns, and alter their distribution within the body. These properties have encouraged their investigation in cancer therapy, gene delivery, vaccine development, antimicrobial treatment, and management of chronic diseases. However, despite considerable scientific progress, the clinical translation of nanomedicines remains challenging because of potential toxicity, biological variability, insufficient targeting efficiency, complex manufacturing procedures, high development costs, and regulatory uncertainties. This review discusses the introduction, advantages, limitations, challenges, pharmaceutical applications, and future prospects of nanotechnology-based drug delivery systems. Emphasis is placed on the need for rational carrier design, comprehensive safety evaluation, reproducible manufacturing, and clinically meaningful therapeutic benefits. Nanotechnology has the potential to improve modern therapeutics, but its success depends on translating laboratory findings into safe, effective, affordable, and clinically validated medicines.

Keywords: Nanotechnology, nanomedicine, drug delivery, nanoparticles, targeted drug delivery, nanotoxicity, controlled release.

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © 2022 Author(s) retain the copyright of this article.

***Corresponding Author**
Dr. Venisetty Raj Kumar

Produced and Published by
South Asian Academic Publications

Introduction

Nanotechnology involves the design, characterization, and application of materials at the nanoscale, commonly within the approximate range of 1–100 nm for nanoscale structures [1]. In pharmaceutical sciences, nanotechnology is used to develop drug delivery systems (DDS) capable of modifying the physicochemical properties, biological distribution, and therapeutic performance of drugs [2]. Nanomedicine combines pharmaceutical science, materials science, biotechnology, and biomedical engineering to improve the prevention, diagnosis, and treatment of diseases [1, 2]. Conventional drug delivery systems, such as tablets, capsules, and injections, have contributed significantly to modern healthcare. Nevertheless, many drugs exhibit poor aqueous solubility, low bioavailability, rapid elimination, enzymatic degradation, or undesirable distribution in healthy tissues. These limitations may necessitate frequent administration or higher doses, potentially increasing adverse effects and reducing patient compliance. Certain therapeutic agents, including nucleic acids, proteins, and some anticancer drugs, also encounter difficulties in crossing biological membranes or reaching intracellular targets [3-8].

Nanotechnology-based drug delivery systems (DDS) have been investigated to address these problems.

Liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, and lipid nanoparticles provide different mechanisms for incorporating and transporting therapeutic agents. Depending on their composition and design, these systems can protect drugs from degradation, enhance solubilization, provide sustained release, or facilitate delivery to particular tissues [1].

The controversy surrounding nanomedicine arises partly from the difference between promising experimental findings and demonstrated clinical benefits. Although nanoscale carriers may improve selected pharmaceutical properties, they do not automatically guarantee efficient targeting, reduced toxicity, or superior therapeutic outcomes [1].

Consequently, nanotechnology should be evaluated as a formulation strategy rather than an inherently superior replacement for conventional drug delivery [2-3]. Its clinical value depends on whether a carefully designed nanocarrier provides measurable advantages over an existing treatment while maintaining acceptable safety, quality, and affordability [1].

Advantages

Nanotechnology provides several potential advantages over conventional drug delivery systems. However, the extent of these benefits depends on the drug, nanocarrier composition, administration route, and disease being treated [1].




Figure 01: Advantages of nanotechnology-based DDS

Improved solubility and bioavailability

Poor aqueous solubility is a major limitation for many pharmaceutical compounds. Nanocrystals and other nanoscale formulations can improve dissolution by increasing the effective surface area available for contact with biological fluids. Lipid-based carriers and polymeric nanoparticles can also incorporate poorly soluble drugs into suitable carrier matrices, potentially improving absorption and systemic exposure [2].

Improved solubilization may reduce formulation difficulties and support more consistent drug absorption. Nevertheless, increased dissolution does not necessarily result in increased bioavailability because intestinal permeability, metabolism, and drug elimination also influence systemic exposure [3].

Controlled and sustained drug release

Nanocarriers can be designed to release drugs gradually through diffusion, carrier degradation, or changes in the surrounding environment. Polymeric nanoparticles, lipid-based carriers, and polymeric micelles can therefore help maintain drug concentrations over an extended period and potentially reduce dosing frequency [5-6].

Controlled release may improve patient convenience and reduce fluctuations in plasma drug concentrations. However, release characteristics must be carefully optimized to prevent premature leakage, incomplete drug release, or prolonged exposure to subtherapeutic concentrations [7].

Targeted drug delivery

Targeted drug delivery aims to increase drug accumulation at a desired tissue or cellular site while limiting exposure to healthy tissues. Passive targeting depends on the biological characteristics of the disease site and the carrier's distribution, whereas active targeting uses surface-associated ligands, antibodies, peptides, or other recognition molecules to interact with specific cellular receptors [5].

These strategies have been extensively investigated in cancer therapy, where conventional chemotherapy may damage both malignant and healthy cells. Nevertheless, active targeting does not guarantee that a nanoparticle will reach the intended tissue, penetrate it, and release its payload effectively [6-8].

Protection of therapeutic agents

Nanocarriers can protect sensitive drugs from hydrolysis, enzymatic degradation, and premature clearance. This property is especially important for nucleic acids, peptides, proteins, and other biologically fragile therapeutic agents.

Lipid nanoparticles, for example, have enabled the delivery of nucleic acid therapeutics by facilitating cellular uptake and protecting the payload during

transport. Such protection can be essential for therapeutic approaches that would otherwise be limited by rapid degradation in biological fluids [9].

Reduction of adverse effects

By changing drug distribution and release, nanocarriers may reduce exposure to certain healthy tissues and improve the therapeutic index of selected drugs. Liposomal formulations of anticancer agents illustrate how reformulation can alter pharmacokinetics and toxicity profiles compared with conventional formulations [10].

However, reduced toxicity cannot be assumed for every nanomedicine. Carrier materials may themselves cause adverse effects, and changes in tissue distribution may introduce new safety concerns. Consequently, toxicity reduction must be demonstrated through appropriate comparative studies [11].

Multifunctionality

Nanocarriers can combine drug delivery with imaging, diagnostic detection, or stimulus-responsive release. These systems support the development of theranostic approaches that integrate therapeutic and diagnostic functions. They may also accommodate more than one therapeutic agent, allowing researchers to investigate combination treatments and coordinated drug release [11-12].Despite this potential, multifunctional systems frequently involve greater formulation complexity, which may increase manufacturing costs and complicate quality control.

Limitations

Although nanotechnology offers promising pharmaceutical applications, several limitations restrict its widespread adoption.




Figure 02: Limitationsof nanotechnology-based DDS

Potential toxicity and biocompatibility

Nanomaterials may interact with cellular membranes, proteins, blood components, and immune cells. Depending on their composition, dose, size, shape, surface charge, and degradation products, certain nanocarriers may produce oxidative stress, inflammation, organ accumulation, or other unwanted biological effects. These effects vary substantially between materials, making product-specific toxicological evaluation essential [13].

Unpredictable biological distribution

After administration, nanoparticles interact with biological fluids and acquire a protein-rich surface layer known as a protein corona. This interaction can alter their identity, circulation time, cellular uptake, and targeting performance. Some nanoparticles are rapidly removed by the mononuclear phagocyte system, particularly in the liver and spleen, limiting the amount of drug reaching the intended site [14].

Limited targeting efficiency

Although targeted nanocarriers are designed to recognize specific cells, actual delivery depends on circulation, vascular permeability, tissue penetration, cellular internalization, and intracellular release. Disease-associated barriers and biological variability can substantially reduce targeting efficiency. Therefore, laboratory demonstrations of receptor binding do not necessarily predict successful delivery in humans [3-5].

Formulation instability

Nanoparticles may undergo aggregation, particle growth, drug leakage, oxidation, or changes in physical structure during storage. Such changes can affect dose uniformity, release characteristics, and product safety. Specialized packaging and storage conditions may be required to maintain stability [15].

High cost and technical complexity

Nanomedicine development often requires advanced equipment, specialized analytical methods, and extensive characterization. These requirements can increase production costs and make some formulations difficult to manufacture economically, particularly in resource-limited healthcare settings [16].

Limited clinical predictability

Favorable findings in cell cultures or animal models may not translate into comparable benefits in humans. Differences in disease biology, immune responses, tissue architecture, and drug metabolism can affect clinical performance. Therefore, the clinical superiority of a

nanocarrier must be established rather than inferred from its nanoscale properties [17].

Challenges

The translation of nanotechnology from laboratory research to routine clinical use remains a major challenge. Several interconnected scientific, manufacturing, regulatory, and economic factors influence the success of nanomedicines.

Physicochemical characterization:

Nanocarriers require detailed characterization of particle size, size distribution, morphology, surface charge, composition, drug-loading capacity, encapsulation efficiency, release kinetics, and stability. These properties influence biological performance and must be controlled throughout development and manufacturing [18].

Conventional analytical methods may not adequately characterize all aspects of complex nanomaterials. Complementary techniques, such as dynamic light scattering, electron microscopy, chromatography, and suitable chemical assays, may be needed to establish product quality. In addition, analytical measurements must be linked to meaningful biological and clinical outcomes [19-20].

Biological barriers and *in vivo* behaviour:

Nanomedicines must overcome multiple biological barriers, including mucus, epithelial layers, vascular endothelium, extracellular matrices, cellular membranes, and intracellular degradation pathways. The blood–brain barrier presents a particularly difficult obstacle for therapies targeting the central nervous system [21].

Manufacturing and scale-up

A formulation prepared successfully in a laboratory may behave differently when manufactured on a larger scale. Changes in mixing, temperature, processing time, material quality, and purification can affect particle size, drug loading, and stability [22].

Safety assessment and regulation:

Nanomedicines require comprehensive evaluation of acute and chronic toxicity, immunogenicity, biodistribution, degradation, and potential accumulation in organs. Standard toxicological methods may need to be supplemented with assessments appropriate to the specific nanomaterial [23].

Cost-effectiveness and clinical evidence:

Developing nanomedicines may require substantial investment in research, specialized manufacturing, clinical trials, and regulatory submissions. Their additional cost must be justified by clinically meaningful benefits, such as improved efficacy, reduced adverse effects, lower dosing frequency, or better patient adherence [24].

Applications

Nanotechnology has been investigated across several therapeutic areas because different nanocarriers can be tailored to the physicochemical properties of drugs and the biological requirements of diseases.

Cancer therapy

Cancer treatment is one of the most established applications of nanomedicine. Conventional anticancer drugs can damage healthy cells in addition to malignant cells, resulting in systemic toxicity. Nanocarriers may modify drug distribution, prolong circulation, and improve drug accumulation in certain tumours [25].

Gene and nucleic acid delivery

Nucleic acid therapeutics, including messenger RNA (mRNA) and small interfering RNA (siRNA), offer opportunities to regulate gene expression or produce therapeutic proteins. However, these molecules can be degraded by nucleases and may not readily cross cellular membranes [26].

Antimicrobial and antifungal therapy

Nanocarriers can modify the distribution and release of antimicrobial agents and may help improve drug exposure at infected tissues. Liposomal amphotericin B is an example of a clinically used lipid-based formulation that changes the distribution and tolerability profile of an antifungal drug [27].

Oral and transdermal drug delivery

Nanotechnology has potential applications in oral and transdermal formulations. Lipid-based nanoparticles, polymeric systems, and nanocrystals can improve the dissolution of poorly soluble drugs. Some formulations are being investigated to protect drugs within the gastrointestinal tract or improve their interaction with intestinal tissues [28].

Central nervous system disorders

The blood–brain barrier restricts the passage of many therapeutic agents into the brain. Nanocarriers modified with selected surface ligands are being investigated to improve drug transport across this barrier [29].

Vaccines and advanced therapeutics

Nanotechnology supports vaccine development by protecting antigens or nucleic acids, facilitating cellular uptake, and enabling controlled presentation of immunological components. Liposomes and lipid

nanoparticles are particularly important in modern vaccine and nucleic acid delivery platforms [30].

Future Prospective

The future of nanotechnology-based drug delivery will depend on the development of safer, more predictable, and clinically relevant nanocarriers. Several research directions are particularly promising.

Stimuli-responsive nanocarriers

Future systems may be designed to release drugs in response to specific biological or external stimuli, including changes in pH, temperature, enzyme activity, or redox conditions. Such approaches could improve spatial and temporal control of drug release. However, the stimulus must be sufficiently specific and reproducible under actual physiological conditions [31].

Personalized nanomedicine

Differences in tumour biology, receptor expression, metabolism, and immune responses can influence nanocarrier performance. Integrating patient-specific biomarkers with formulation design may help identify individuals most likely to benefit from particular nanomedicines. This approach requires validated biomarkers and evidence that patient selection improves clinical outcomes [32].

Improved targeting and intracellular delivery

Future research should focus on overcoming biological barriers rather than relying exclusively on surface ligands or prolonged circulation. Strategies that improve tissue penetration, cellular uptake, endosomal escape, and intracellular payload release may enhance the therapeutic performance of nucleic acid and other advanced therapeutics [33].

Safer and biodegradable materials

Biodegradable polymers, physiologically compatible lipids, and materials with predictable elimination profiles may reduce concerns about long-term accumulation. Future studies should investigate degradation products, immune responses, repeated-dose toxicity, and interactions with biological systems [34].

Advanced manufacturing and quality control

Microfluidic production, process automation, and real-time monitoring may improve batch-to-batch consistency and facilitate scale-up. Standardized analytical methods and early identification of critical quality attributes will be important for ensuring product quality and reproducibility [35].

Regulatory development and affordability

Clearer regulatory expectations, reliable safety assessment methods, and collaboration among researchers, manufacturers, and regulatory agencies could accelerate clinical translation. Manufacturing processes should also be optimized to make successful nanomedicines affordable and accessible, particularly in low- and middle-income countries [36-38].

Conclusion

Nanotechnology represents an important advancement in pharmaceutical drug delivery because it provides opportunities to modify the solubility, stability, release, and biological distribution of therapeutic agents. Liposomes, polymeric nanoparticles, lipid nanoparticles, micelles, and nanocrystals have different advantages and can be selected according to the characteristics of the drug and the intended therapeutic application. Overall, nanotechnology should be regarded as a valuable but application-dependent pharmaceutical strategy. Its importance lies not simply in producing smaller particles, but in demonstrating that nanoscale engineering provides a clinically meaningful advantage over conventional treatment.

References

1. Devadasu VR, Bhardwaj V, Kumar MNV. Can controversial nanotechnology promise drug delivery? Chem Rev. 2013;113(3):1686-1735.
2. Geetha A, Rajendra K, Krishna MC, Satish V, Raju P. A review on floating drug delivery systems. Int J Pharm Res Biomed Anal. 2012;1:1-3.
3. Jadi RK, Bomma R, Sellappan V. Development of a new single unit dosage form of propranolol HCl extended release non-effervescent floating matrix tablets: In vitro and in vivo evaluation. Journal of applied pharmaceutical science. 2016;6(5):112-8.
4. Jadi RK, Chinnala KM. A comprehensive review on gastroretentive drug Delivery systems. Indo American Journal of Pharmaceutical sciences. 2016;3(2):115-28.
5. Togaru V, Venisetty RK, Bakshi V, Jadi RK. Formulation development and in vitro evaluation of propranolol hydrochloride extended release matrixtablets Emergent life sciences research. 2017;3:38-47.
6. Prasad RR, Kumar JR, Vasudha BA, Kumar CA. Formulation development and evaluation of

allopurinol solid dispersions by solvent evaporation technique. Int J Appl Pharm. 2018;10(4):168-71.

7. Pandala S, Bakshi V, Jadi RK. Formulation development and in vitro characterization of zolmitriptan controlled release drug delivery systems. INNOSC Theranostics Pharmacol. Sci. 2019;2(1):6-11.
8. Sapavatu SN, Jadi RK. Formulation development and characterization of gastroretentive drug delivery systems of loratadine. International journal of applied pharmaceutics. 2019;11(6):91-9.
9. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
10. Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-34.
11. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-24.
12. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078-94.
13. Kaur IP, Kakkar V, Deol PK, Yadav M, Singh M, Sharma I. Issues and concerns in nanotech product development and its commercialization. Journal of Controlled Release. 2014;193:51-62.
14. Melbourne BA, Hastings A. Highly variable spread rates in replicated biological invasions: fundamental limits to predictability. Science. 2009;325(5947):1536-9.
15. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. Journal of pharmaceutical sciences. 2007;96(1):1-26.
16. Eslavath RN, Bakshi V, Jadi RK. Formulation Development and In Vitro Release Studies of Tenofovir-containing Microsponges. INNOSC Theranostics and pharmacological sciences. 2019;2(2):16-24.
17. Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochemical pharmacology. 2014;87(1):150-61.
18. Hallan SS, Sguizzato M, Esposito E, Cortesi R. Challenges in the physical characterization of lipid nanoparticles. Pharmaceutics. 2021;13(4):549.
19. Sapavatu SN, Jadi RK. Development of floating drug delivery system for loratadine: in vitro and in vivo evaluation. International journal of pharmaceutical sciences and research. 2020;11:3021-2.
20. Sapavatu SN, Chinthala R, Jadi RK. An overview on Pharmacokinetics of Polymeric Nanoparticles Intended for Oral Delivery. Journal of Young Pharmacists. 2020;12(3):187.
21. Gao C, Wang Y, Ye Z, Lin Z, Ma X, He Q. Biomedical micro-/nanomotors: from overcoming biological barriers to in vivo imaging. Advanced Materials. 2021;33(6):2000512.
22. Crater JS, Lievense JC. Scale-up of industrial microbial processes. FEMS microbiology letters. 2018;365(13):fny138.
23. Coglianese C, Nash J, Olmstead T. Performance-based regulation: Prospects and limitations in health, safety, and environmental protection. Admin. L. Rev. 2003;55:705.
24. Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circulation: Cardiovascular Quality and Outcomes. 2009;2(1):55-8.
25. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nano-enabled medical applications. 2020:61-91.
26. Guo X, Huang L. Recent advances in nonviral vectors for gene delivery. Accounts of chemical research. 2012;45(7):971-9.
27. Fernández de Ullivarri M, Arbulu S, Garcia-Gutierrez E, Cotter PD. Antifungal peptides as therapeutic agents. Frontiers in Cellular and Infection Microbiology. 2020;10:105.
28. Chime SA, Kenechukwu FC, Attama AA. Characterization and Applications in Drug Delivery. Application of nanotechnology in drug delivery. 2014;77.
29. Lauraitis A, Maskeliūnas R, Damaševičius R, Połap D, Woźniak M. A smartphone application for automated decision support in cognitive task based evaluation of central nervous system motor disorders. IEEE journal of biomedical and health informatics. 2019;23(5):1865-76.
30. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nature reviews Drug discovery. 2014;13(10):759-80.
31. El-Sawy HS, Al-Abd AM, Ahmed TA, El-Say KM, Torchilin VP. Stimuli-responsive nano-architecture drug-delivery systems to solid tumor micromilieu: past, present, and future perspectives. ACS nano. 2018;12(11):10636-64.

32. Ryu JH, Lee S, Son S, Kim SH, Leary JF, Choi K, Kwon IC. Theranostic nanoparticles for future personalized medicine. Journal of controlled release. 2014;190:477-84.
33. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng.2006;8(1):343-75.
34. Ahmed T, Shahid M, Azeem F, Rasul I, Shah AA, Noman M, Hameed A, Manzoor N, Manzoor I, Muhammad S. Biodegradation of plastics: current scenario and future prospects for environmental safety. Environmental science and pollution research. 2018;25(8):7287-98.
35. Arinez JF, Chang Q, Gao RX, Xu C, Zhang J. Artificial intelligence in advanced manufacturing: Current status and future outlook. Journal of Manufacturing Science and Engineering. 2020;142(11):110804.
36. Wetzstein S. The global urban housing affordability crisis. Urban studies. 2017;54(14):3159-77.
37. Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-134.
38. Naga Pranathi A, Narender B, Lakshmi Madhuri Y. Preparation of Silver Nanoparticles from Herbal Plant. Indo American Journal of Pharmaceutical Sciences. 2018; 05(04):3159-67.